MAP kinase MEKK1, coded by MAP3K1, has been reported to promote cancer cell migration by contributing to an accommodating breast tumor microenvironment [43, 44], while FGFR2 has been identified as a viable drug target in breast cancer [45]. Here, FGFR2 is linked to breast carcinoma.